Our country accelerates the development of innovative drugs! Policy cooperation is crucial in bridging the "last mile" to getting them approved for clinical use.

Since the beginning of this year, there have been frequent reports of breakthroughs in the field of innovative drugs in China, with dozens of original innovative drugs being approved for market one after another. However, a new drug often takes ten years or even longer to go from research and development to market. From experimentation in the laboratory, to clinical verification involving thousands of patients, and then to rigorous approval, innovative drugs must overcome numerous challenges. From target discovery to evaluation and approval, the "road to market" for a single innovative drug has a total cost exceeding $1 billion. Data shows that from January to July this year, the National Medical Products Administration has approved the market launch of 50 innovative drugs, exceeding the total of 48 for the entire previous year. During the "14th Five-Year Plan" period, the National Medical Products Administration has approved a total of 210 innovative drugs, maintaining a trend of accelerated growth. In addition, China ranks among the top in the world in terms of innovative drug pipelines and the number of clinical trial projects, with strong momentum in pharmaceutical innovation.